Technical Analysis for VAL - Valirx Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.00% |
| Alert | Time |
|---|---|
| Down 1% | about 19 hours ago |
| Possible Inside Day | about 19 hours ago |
| Possible NR7 | about 19 hours ago |
| Possible NR7 | 2 days ago |
| 5x Volume Pace | 2 days ago |
Free Daily (Stock) Chart Reading
Valirx Plc Description
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Engineering Biotechnology Pharmaceutical Medicine Life Sciences Cancer Disease Pipe Clinic Biopharmaceutical Oncology Clinical Trial Drug Development Biomarker Biomarkers Treatment Of Cancer Prostate Cancer Treatment Of Prostate Cancer Cancer Screening Chemical Pathology Companion Diagnostic
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.0 |
| 52 Week Low | 3.3 |
| Average Volume | 798,688 |
| 200-Day Moving Average | 6.74 |
| 50-Day Moving Average | 3.91 |
| 20-Day Moving Average | 3.58 |
| 10-Day Moving Average | 3.54 |
| Average True Range | 0.16 |
| RSI (14) | 27.54 |
| ADX | 18.13 |
| +DI | 15.27 |
| -DI | 20.70 |
| Chandelier Exit (Long, 3 ATRs) | 3.41 |
| Chandelier Exit (Short, 3 ATRs) | 3.79 |
| Upper Bollinger Bands | 3.81 |
| Lower Bollinger Band | 3.35 |
| Percent B (%b) | 0.22 |
| BandWidth | 12.75 |
| MACD Line | -0.13 |
| MACD Signal Line | -0.14 |
| MACD Histogram | 0.0112 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.51 | ||||
| Resistance 3 (R3) | 3.51 | 3.48 | 3.50 | ||
| Resistance 2 (R2) | 3.48 | 3.46 | 3.48 | 3.50 | |
| Resistance 1 (R1) | 3.46 | 3.45 | 3.47 | 3.47 | 3.50 |
| Pivot Point | 3.44 | 3.44 | 3.44 | 3.44 | 3.44 |
| Support 1 (S1) | 3.42 | 3.42 | 3.43 | 3.43 | 3.40 |
| Support 2 (S2) | 3.39 | 3.41 | 3.40 | 3.40 | |
| Support 3 (S3) | 3.38 | 3.39 | 3.40 | ||
| Support 4 (S4) | 3.39 |
